IP Verse

Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab - EP2766040

The patent EP2766040 was granted to F Hoffmann LA Roche on May 15, 2019. The application was originally filed on Oct 11, 2012 under application number EP12778010A. The patent is currently recorded with a legal status of "Revoked".

EP2766040

F HOFFMANN LA ROCHE
Application Number
EP12778010A
Filing Date
Oct 11, 2012
Status
Revoked
Jun 10, 2022
Grant Date
May 15, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR REDDYS LABORATORIESFeb 17, 2020NEUEFEINDADMISSIBLE
LEDLFeb 17, 2020LEDLADMISSIBLE
EUROPEAN OPPOSITIONSFeb 14, 2020KILBURN & STRODEADMISSIBLE
J A KEMPFeb 14, 2020J A KEMPADMISSIBLE
POHLMANFeb 14, 2020POHLMANADMISSIBLE
ROTHFeb 14, 2020ROTHADMISSIBLE
GILL JENNINGS & EVERYFeb 13, 2020GILL JENNINGS & EVERYADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEFeb 13, 2020HEMSATHADMISSIBLE
DR H ULRICH DORRIESFeb 13, 2020DORRIESWITHDRAWN
DR H ULRICH DORRIESFeb 13, 2020DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANWITHDRAWN

Patent Citations (215) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2001014326
DESCRIPTIONUS2002001587
DESCRIPTIONUS2002035736
DESCRIPTIONUS2002064785
DESCRIPTIONUS2002090662
DESCRIPTIONUS2002136719
DESCRIPTIONUS2003134344
DESCRIPTIONUS2003147884
DESCRIPTIONUS2003152987
DESCRIPTIONUS2003170234
DESCRIPTIONUS2003202972
DESCRIPTIONUS2004037823
DESCRIPTIONUS2004082047
DESCRIPTIONUS2004106161
DESCRIPTIONUS2004258685
DESCRIPTIONUS2005002928
DESCRIPTIONUS2005063972
DESCRIPTIONUS2005100944
DESCRIPTIONUS2005208043
DESCRIPTIONUS2005238640
DESCRIPTIONUS2005244417
DESCRIPTIONUS2005244929
DESCRIPTIONUS2005276812
DESCRIPTIONUS2006013819
DESCRIPTIONUS2006018899
DESCRIPTIONUS2006034840
DESCRIPTIONUS2006034842
DESCRIPTIONUS2006046270
DESCRIPTIONUS2006067930
DESCRIPTIONUS2006073143
DESCRIPTIONUS2006083739
DESCRIPTIONUS2006088523
DESCRIPTIONUS2006099201
DESCRIPTIONUS2006121044
DESCRIPTIONUS2006165702
DESCRIPTIONUS2006182739
DESCRIPTIONUS2006183150
DESCRIPTIONUS2006188509
DESCRIPTIONUS2006193854
DESCRIPTIONUS2006198843
DESCRIPTIONUS2006204505
DESCRIPTIONUS2006210561
DESCRIPTIONUS2006212956
DESCRIPTIONUS2006275305
DESCRIPTIONUS2007009976
DESCRIPTIONUS2007020261
DESCRIPTIONUS2007026001
DESCRIPTIONUS2007037228
DESCRIPTIONUS2007166753
DESCRIPTIONUS2007184055
DESCRIPTIONUS2007224203
DESCRIPTIONUS2007269429
DESCRIPTIONUS2007292419
DESCRIPTIONUS2008038271
DESCRIPTIONUS2008050373
DESCRIPTIONUS2008050385
DESCRIPTIONUS2008050748
DESCRIPTIONUS2008102069
DESCRIPTIONUS2008108096
DESCRIPTIONUS2008112958
DESCRIPTIONUS2008160026
DESCRIPTIONUS2008171040
DESCRIPTIONUS2008187533
DESCRIPTIONUS2008226659
DESCRIPTIONUS2008241146
DESCRIPTIONUS2008286280
DESCRIPTIONUS2008317753
DESCRIPTIONUS2009081223
DESCRIPTIONUS2009087432
DESCRIPTIONUS2009098135
DESCRIPTIONUS2009099344
DESCRIPTIONUS2009137387
DESCRIPTIONUS2009148402
DESCRIPTIONUS2009148435
DESCRIPTIONUS2009155259
DESCRIPTIONUS2009155803
DESCRIPTIONUS2009187007
DESCRIPTIONUS2009202536
DESCRIPTIONUS2009202546
DESCRIPTIONUS2009220492
DESCRIPTIONUS2009226455
DESCRIPTIONUS2009239236
DESCRIPTIONUS2009285837
DESCRIPTIONUS2009317387
DESCRIPTIONUS2010008975
DESCRIPTIONUS2010015157
DESCRIPTIONUS2010016556
DESCRIPTIONUS2010112603
DESCRIPTIONUS2010120053
DESCRIPTIONUS2010158899
DESCRIPTIONUS2010285010
DESCRIPTIONUS2010298156
DESCRIPTIONUS2011027190
DESCRIPTIONUS2011033460
DESCRIPTIONUS2011044977
DESCRIPTIONUS2011064736
DESCRIPTIONUS2011064737
DESCRIPTIONUS2011117096
DESCRIPTIONUS2011117097
DESCRIPTIONUS2011129464
DESCRIPTIONUS2011151454
DESCRIPTIONUS2011159014
DESCRIPTIONUS2011165157
DESCRIPTIONUS2011223159
DESCRIPTIONUS2011223619
DESCRIPTIONUS2011236383
DESCRIPTIONUS2011245103
DESCRIPTIONUS2011246399
DESCRIPTIONUS2011250194
DESCRIPTIONUS2012003217
DESCRIPTIONUS2012034213
DESCRIPTIONUS2012034609
DESCRIPTIONUS2012065381
DESCRIPTIONUS2012093838
DESCRIPTIONUS2012107302
DESCRIPTIONUS2012107391
DESCRIPTIONUS2012121586
DESCRIPTIONUS4816567
DESCRIPTIONUS4933294
DESCRIPTIONUS4968603
DESCRIPTIONUS5183884
DESCRIPTIONUS5401638
DESCRIPTIONUS5480968
DESCRIPTIONUS5648237
DESCRIPTIONUS5677171
DESCRIPTIONUS5720937
DESCRIPTIONUS5720954
DESCRIPTIONUS5725856
DESCRIPTIONUS5770195
DESCRIPTIONUS5772997
DESCRIPTIONUS5821337
DESCRIPTIONUS6015567
DESCRIPTIONUS6054297
DESCRIPTIONUS6127526
DESCRIPTIONUS6165464
DESCRIPTIONUS6267958
DESCRIPTIONUS6333169
DESCRIPTIONUS6333398
DESCRIPTIONUS6339142
DESCRIPTIONUS6387371
DESCRIPTIONUS6399063
DESCRIPTIONUS6407213
DESCRIPTIONUS6417335
DESCRIPTIONUS6489447
DESCRIPTIONUS6573043
DESCRIPTIONUS6627196
DESCRIPTIONUS6632979
DESCRIPTIONUS6639055
DESCRIPTIONUS6685940
DESCRIPTIONUS6719971
DESCRIPTIONUS6797814
DESCRIPTIONUS6800738
DESCRIPTIONUS6821515
DESCRIPTIONUS6905830
DESCRIPTIONUS6949245
DESCRIPTIONUS6984494
DESCRIPTIONUS7018809
DESCRIPTIONUS7041292
DESCRIPTIONUS7060268
DESCRIPTIONUS7074404
DESCRIPTIONUS7097840
DESCRIPTIONUS7129051
DESCRIPTIONUS7279287
DESCRIPTIONUS7344840
DESCRIPTIONUS7371376
DESCRIPTIONUS7371379
DESCRIPTIONUS7435797
DESCRIPTIONUS7449184
DESCRIPTIONUS7468252
DESCRIPTIONUS7485302
DESCRIPTIONUS7485704
DESCRIPTIONUS7498030
DESCRIPTIONUS7501122
DESCRIPTIONUS7531645
DESCRIPTIONUS7537931
DESCRIPTIONUS7560111
DESCRIPTIONUS7575748
DESCRIPTIONUS7618631
DESCRIPTIONUS7674589
DESCRIPTIONUS7682609
DESCRIPTIONUS7700299
DESCRIPTIONUS7807799
DESCRIPTIONUS7811773
DESCRIPTIONUS7846441
DESCRIPTIONUS7850966
DESCRIPTIONUS7862817
DESCRIPTIONUS7879325
DESCRIPTIONUS7892549
DESCRIPTIONUS7919254
DESCRIPTIONUS7981418
DESCRIPTIONUS7993834
DESCRIPTIONUS8044017
DESCRIPTIONUS8075890
DESCRIPTIONUS8075892
DESCRIPTIONUS8076066
DESCRIPTIONUS8142784
DESCRIPTIONUS8163287
DESCRIPTIONUS8241630
DESCRIPTIONUS8247397
DESCRIPTIONWO0189566
DESCRIPTIONWO2009154651
DESCRIPTIONWO9105264
DESCRIPTIONWO9704801
DESCRIPTIONWO9845479
DESCRIPTIONWO9931140
INTERNATIONAL-SEARCH-REPORTUS2008102069
INTERNATIONAL-SEARCH-REPORTWO2009154651
OPPOSITIONEP1846030
OPPOSITIONUS2005208043
OPPOSITIONUS2006275305
OPPOSITIONWO0100245
OPPOSITIONWO2006009861
OPPOSITIONWO2006078307
OPPOSITIONWO2009154651
OPPOSITIONWO2013055874

Non-Patent Literature (NPL) Citations (94) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- FORBES ET AL., "BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC)", JOURNAL OF CLINICAL ONCOLOGY, (2006), vol. 24, no. 18S-
EXAMINATION- GNANT MICHAEL ET AL, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.", THE LANCET. ONCOLOGY JUL 2011, (201107), vol. 12, no. 7, ISSN 1474-5488, pages 631 - 641-
EXAMINATION- MUSS HYMAN B ET AL, "Adjuvant chemotherapy in older women with early-stage breast cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 14 MAY 2009, (20090514), vol. 360, no. 20, ISSN 1533-4406, pages 2055 - 2065-
OPPOSITION- A.K. Jayaram, Et Al, "Neoadjuvant Trastuzumab, Docetaxel, and Carboplatin (TCH) for Human Epidermal Growth Factor Receptor -2 (HER-2) Positive Breast Cancer: Pathological Tumour Response Rates in an Irish Teaching Hospital", Annal of Oncology, (20101001), vol. 21, no. 8, page VIII113, XP055687253-
OPPOSITION- Anonymous, "Breast Cancer Treatment Guidelines for Patients", Breast Cancer Treatment Guidelines for Patients version VIII, American Cancer Society and NCCN, pages 1 - 92, Breast Cancer Treatment Guidelines for Patients version VIII, URL: https://screening.iarc.fr/doc/Breast_VIII.pdf, (20200428), XP055689834-
OPPOSITION- Anonymous, "Early-Stage Breast Cancer More Deadly in Men Than Women", breastcancer.org, page 1, breastcancer.org, URL: https://www.breastcancer.org/research-news/20070509, (20200429), XP055690209-
OPPOSITION- Anonymous, "Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor Disappearance in Study of Wom", FierceBiotech, pages 1 - 4, FierceBiotech, URL: https://www.fiercebiotech.com/biotech/pertuzumab-and-herceptin-plus-chemotherapy-significantly-improved-rate-of-complete-tumor, (20200511), XP055693525-
OPPOSITION- CHU et al., "Principles of Cancer Management: Chemotherapy", Cancer: Principles & Practice of Oncology, (20010000), pages 289 - 306, XP055694919-
OPPOSITION- "Early-stage breast cancer", entry in the NCI Dictionary of Cancer Terms serves to illustrate the technical background and the technical understanding of the skilled person-
OPPOSITION- EXCERPT FROM THE NCT00976989 CLINICAL TRIAL, 20 September 2011 (2011-09-20), XP55686232, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT00976989? A=27 &B=27 &C=me rged#StudyPage Top>, XP055686232-
OPPOSITION- Frederick L. Greene, AJCC Cancer Staging Manual Sixth Edition, SPRINGER, (20020510), vol. 1, ISBN 0-387-95271-3, XP002752116-
OPPOSITION- G C PRENDERGAST et al., Cancer Immunotherapy: Immune Suppression and Tumor Growth, (20070802), vol. 7, pages 101 - 116, XP55685965-
OPPOSITION- Han, Et Al, "Dose-dense docetaxel, carboplatinum and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor-2 - positive stage II and III breast cancer", Breast Cancer Research and Treatment, (20071201), page s226, XP055693566-
OPPOSITION- Hoffmann La-Roche, "A study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER-2Positive Breast Cancer", Australian New Zealand Clinical Trials Registry (ANZCTR), Trial Details for Study: NCT00976989, (20090915), Australian New Zealand Clinical Trials Registry (ANZCTR), Trial Details for Study: NCT00976989, URL: https://www.anzctr.orq.au/Trial/Reg istration/Trial Review.aspx?id=7345&isClinicalTrial=True, (20200415), XP055685883-
OPPOSITION- Hoffmann - La Roche, "A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer", Key Record Dates for Study : NCT00976989, Clinicaltrials.gov, (20090914), Key Record Dates for Study : NCT00976989, URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V 29=View#StudyPageTop, (20200415), XP055685902-
OPPOSITION- Hoffmann-La Roche, "A study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Pasitive Breast Cancer", National Institute of Health (NIH) History of Changes for Study: NCT00976989, (20090915), National Institute of Health (NIH) History of Changes for Study: NCT00976989, URL: https://clinicaltrials.gov/ct2/historv/NCT00976989?V1=View#StudyPaqeTop:first, (20200415), XP055685862-
OPPOSITION- Hoffmann-La Roche, "A study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Pasitive Breast Cancer", National Institute of Health (NIH) History of Changes for Study: NCT00976989, (20111115), XP055685862-
OPPOSITION- Hoffmann - La Roche, "A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer", Excerpt from the NCT00976989 clinical trial, URL: https://clinicaltrials.gov/ct2/history/NCT00976989?A=27&B=27&C=merged#StudyPageTop, (20200416), XP055686232-
OPPOSITION- Hoffmann -La Roche, "A Study of Pertuzumab in Combination With Herceptin and Chemotherapy With HER2-Positive Breast Cancer", ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT00976989, (20200415), XP055686037-
OPPOSITION- HOFFMANN LA-ROCHE, Australian New Zealand Clinical Trials Registry (ANZCTR), Trial Details for Study: NCT00976989, (20090915), URL: https://www.anzctr.orq.au/Trial/Reg istration/Trial Review.aspx?id=7345&isClinicalTrial=True, XP55685883-
OPPOSITION- HOFFMANN-LA ROCHE, History of Changes for Study: NCT00545688, (20071016), URL: https://clinicaltrials.gov/ct2/history/NCT00545688?V1=View#StudyPageTop, XP55685951-
OPPOSITION- HOFFMANN-LA ROCHE, Key Record Dates for Study, (20090915), URL: https://clinicaltrials.qov/ct2/keydates/NCT00976989, XP55685877-
OPPOSITION- HOFFMANN-LA ROCHE, Key Record Dates for Study : NCT00976989, (20091115), URL: https://clinicaltrials.gov/ct2/history/NCT00976989?V 29=View#StudyPageTop, XP55685902-
OPPOSITION- Hoffmann-La Roche , National Institute of Health (NIH) History of Changes for Study: NCT00976989, (20090915), URL: https://clinicaltrials.gov/ct2/historv/NCT00976989?V1=View#StudyPaqeTop:first, XP55685862-
OPPOSITION- M Pegram, "Breast cancer: review of platinum-based cooperative group trials.", J Natl Compr Canc Netw., (20040902), vol. supl 2, pages S2 - S9, XP055693560-
OPPOSITION- Nine months YTD 2011 sales, (20111013), URL: https://www.roche.com/dam/icr:b1 7c1 ffa-80d4-4e1 b-b3 cd - b8f3a1717af7/en/irp3q11 e.pdf-
OPPOSITION- PEGRAM et al., "Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer", Journal of the National Cancer Institute, (20040000), vol. 96, pages 739 - 749, XP009058594-
OPPOSITION- PEGRAM et al., "Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer", Journal of the National Cancer Institute, (20040519), vol. 96, no. 10, pages 739 - 749, XP009058594-
OPPOSITION- PEGRAM M D, ET AL., "RATIONAL COMBINATIONS OF TRASTUZUMAB WITH CHEMOTHERAPEUTIC DRUGS USED IN THE TREATMENT OF BREAST CANCER", JOURNAL OF THE NATIONAL CANCER INSTITUTE, Oxford University Press, GB, GB, (20040519), vol. 96, no. 10, ISSN 0027-8874, pages 739 - 749, XP009058594-
OPPOSITION- Roche Media Release, (20111130), URL: https://www.roche.com/dam/icr:e32f53c2-251c-4432-8bf6-32fa5efc0764/en/med-cor-2011-11-30-e.pdf, XP55685954-
OPPOSITION- Roche, "Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium", Roche Media Release, Roche Media Release, URL: https://www.roche.com/dam/icr:e32f53c2-251c-4432-8bf6-32fa5efc0764/en/med-cor-2011-11-30-e.pdf, (20200415), XP055685954-
OPPOSITION- ROCHE'S INVESTOR UPDATE, 10 December 2010 (2010-12-10), XP055694942, Retrieved from the Internet <URL:https://www.roche.com/investors/updates/inv-update- 2010-12-10 .htm>-
OPPOSITION- Roche's Media Release, (20111130), URL: https://www.roche.com/media/releases/med-cor- 2011-11 -30 .htm, XP055685954-
OPPOSITION- S B KAYE et al., "A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer", Journal of Clinical Oncology, (20080520), pages 1 - 5, XP55685969-
OPPOSITION- S.B. Kaye, Et Al, "A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer", Journal of Clinical Oncology, (20080520), vol. 26, no. 15, pages 1 - 5, XP055685969-
OPPOSITION- Soley Bayraktar, Et Al, "Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer", Cancer, (20120501), vol. 118, no. 9, pages 2385 - 2393, XP055693558-
OPPOSITION- South Central - Hampshire B Research Ethics Committee, NHS Health Research Authority, BO22280 Pertuzumab + Trastuzumab in HER2+ Early BC (NeoAdjuvant, (20090917), URL: https://www.hra.nhs.uk/planninq-and-improvinq-research/application-summaries/research-summaries/bo22280-pertuzumab-trastuzumab-in-her2-early-bc-neoadjuvant, XP55685892-
OPPOSITION- Valero, "Future direction of neoadjuvant therapy for breast cancer", Semin Oncol, (19980401), vol. 25, no. 2, pages 36 - 41, XP055634677-
OPPOSITION- H. Charfare, Et Al, "Neoadjuvant chemotherapy in breast cancer", British Journal of Surgery, John Wiley & Sons Ltd, (20050101), vol. 92, pages 14 - 23, XP055686448
OPPOSITION- CHANG et al., "Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment", Cancer, (20100000), vol. 116, no. 18, pages 4227 - 4237, XP055686270
OPPOSITION- CHANG et al., "Differential response to Triple-Negative Breast Cancer to a Docetaxel and Carboplatin-Based Neoadjuvant Treatment", Cancer, (20100915), vol. 116, pages 4227 - 37, XP055686270
OPPOSITION- Helena R. Chang, Et Al, "Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment", CANCER., AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, US, (20100915), vol. 116, no. 18, doi:10.1002/cncr.25309, ISSN 0008-543X, pages 4227 - 4237, XP055686270
OPPOSITION- Eugene R. Ahn; Charles L. Vogel, "Dual HER2-targeted approaches in HER2-positive breast cancer", Breast Cancer Research and Treatment, Kluwer Academic Publishers, Bo, Bo, (20110929), vol. 131, no. 2, doi:10.1007/s10549-011-1781-y, ISSN 1573-7217, pages 371 - 383, XP019994873
OPPOSITION- Antonis Valachis; Davide Mauri; Nikolaos P. Polyzos; Grigoris Chlouverakis; Dimitrios Mavroudis; Vassilios Georgoulias;, "Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis", BREAST, EDINBURGH, GB, GB, (20110629), vol. 20, no. 6, doi:10.1016/j.breast.2011.06.009, ISSN 0960-9776, pages 485 - 490, XP028121161
OPPOSITION- E Mamounas, "Preoperative (neoadjuvant) chemotherapy in patients with breast cancer", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, US, (20010801), vol. 28, no. 4, doi:10.1016/S0093-7754(01)90132-0, ISSN 0093-7754, pages 389 - 399, XP055686457
OPPOSITION- J M NABHOLTZ et al., "Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over- expressing the HER2-neu proto- oncogene", Poster, European Journal of Cancer, (20011000), vol. 37, no. 6, page 190, XP004477936
OPPOSITION- L. Gianni, Et Al, "Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE)", The Breast, (20110301), vol. 20, no. Suppl. 1, doi:10.1016/S0960-9776(11)70241-7, page S73, XP055687184
OPPOSITION- H.-C. Kolberg, Et Al, "Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer", The Breast, (20110318), vol. 20, no. 6, page S74, XP055687247
OPPOSITION- J CROWN et al., "Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy", Breast Cancer Research and Treatment, (20030300), vol. 79, no. 1, pages S11 - S 18, XP002639751
OPPOSITION- Rohit Bhargava, Et Al, "Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer", Modern Pathology, Nature Publishing Group, GB, GB, (20110301), vol. 24, no. 3, doi:10.1038/modpathol.2010.209, ISSN 0893-3952, pages 367 - 374, XP055693546
OPPOSITION- Dennis Slamon et al, "Adjuvant Trastuzumab in HER2-Positive Breast Cancer", New England Journal of Medicine, New England Journal of Medicine, (20111006), vol. 365, no. 14, doi:10.1056/NEJMoa0910383, ISSN 0028-4793, pages 1273 - 1283, XP055056923
OPPOSITION- Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki, Tamas Pinter, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gunter Von Minckwitz, Frances Visco, Valerie Bee, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, Alessandro Riva, John Crown, "Adjuvant Trastuzumab in HER2-Positive Breast Cancer", New England Journal of Medicine, New England Journal of Medicine, (20111006), vol. 365, no. 14, doi:10.1056/NEJMoa0910383, ISSN 00284793, pages 1273 - 1283, XP055056923
OPPOSITION- SLAMON et al., "Adjuvant Trastuzumab in HER2-positive breast cancer", N Engl J med 365, (20111006), vol. 14, doi:10.1056/NEJMoa0910383, pages 1273 - 1283, XP055056923
OPPOSITION- SLAMON et al., "Adjuvant trastuzumab in HER2-positive breast cancer", The New England Journal of Medicine, (20111000), vol. 365, no. 14, doi:10.1056/NEJMoa0910383, pages 1273 - 1283, XP055056923
OPPOSITION- S. Guiu, Et Al, "Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy", ANNALS OF ONCOLOGY., KLUWER, DORDRECHT., NL, NL, (20110201), vol. 22, no. 2, doi:10.1093/annonc/mdq397, ISSN 0923-7534, pages 321 - 328, XP055687199
OPPOSITION- D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross, J. Baselga, "Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab", Annals of Oncology, Kluwer Academic Publishers, (20120301), vol. 23, no. 3, doi:10.1093/annonc/mdr294, ISSN 09237534, pages 791 - 800, XP055056836
OPPOSITION- SCHNEEWEISS et al., "Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER 2- positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA", Annals of Oncology, (20130000), vol. 24, doi:10.1093/annonc/mdt182, pages 2278 - 2284, XP055473044
OPPOSITION- M. D. Pegram et al, "Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer", JOURNAL OF THE NATIONAL CANCER INSTITUTE, Oxford University Press, GB, GB, (20040519), vol. 96, no. 10, doi:10.1093/jnci/djh133, ISSN 0027-8874, pages 759 - 769, XP055693563
OPPOSITION- NAHTA R. et al, "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", Cancer research, US, (20040401), vol. 64, no. 7, doi:10.1158/0008-5472.CAN-03-3856, ISSN 0008-5472, pages 2343 - 2346, XP002521223
OPPOSITION- R NAHTA et al., "The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells", Cancer Research, (20040401), vol. 64, doi:10.1158/0008-5472.CAN-03-3856, pages 2343 - 2346, XP002521223
OPPOSITION- SCHEUER et al., "Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models", Cancer Res, (20091124), vol. 69, doi:10.1158/0008-5472.CAN-08-4597, pages 9330 - 9336, XP055029437
OPPOSITION- W SCHEUER et al., "Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models", Cancer Research, (20091124), vol. 69, no. 24, pages 9930 - 9936, XP055029437
OPPOSITION- W. Scheuer et al, "Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models", Cancer research, US, (20091215), vol. 69, no. 24, doi:10.1158/0008-5472.CAN-08-4597, ISSN 00085472, pages 9330 - 9336, XP055029437
OPPOSITION- W. Scheuer, T. Friess, H. Burtscher, B. Bossenmaier, J. Endl, M. Hasmann, "Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models", Cancer research, American Association for Cancer Research, (20091215), vol. 69, no. 24, doi:10.1158/0008-5472.CAN-08-4597, ISSN 00085472, pages 9330 - 9336, XP055029437
OPPOSITION- H.R. Chang, Et Al, "Clinical Advantages of Neoadjuvant Docetaxel (T) and Carboplatin (C) ± Trastuzumab (H) in locally Advanced Breast Cancer (LABC)", Cancer Research, Abstract 1100, (20091215), vol. 24, page 571S, XP055686473
OPPOSITION- GIANNI et al., "Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere", Cancer Research, (20100000), vol. 70, no. 24, XP009166330
OPPOSITION- GIANNI L et al., "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere", Cancer Res 2010, (20101215), vol. 70, doi:10.1158/0008-5472.SABCS10-S3-2, XP009166330
OPPOSITION- L Gianni et al, "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')", Cancer research, American Association for Cancer Research, US, US, (20101215), vol. 70, no. 24, Suppl.2, doi:10.1158/0008-5472.SABCS10-S3-2, ISSN 0008-5472, pages 3 - 2, XP009166330
OPPOSITION- L Gianni et al, "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')", Cancer research, American Association for Cancer Research, US, US, (20101215), vol. 70, no. 24, Suppl.2, doi:10.1158/0008-5472.SABCS10-S3-2, ISSN 0008-5472, XP009166330
OPPOSITION- L Gianni et al, "Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')", Cancer research, US, (20101215), vol. 70, no. 24, Suppl.2, doi:10.1158/0008-5472.SABCS10-S3-2, ISSN 0008-5472, XP009166330
OPPOSITION- A Schneeweiss et al, "Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).", Cancer research, American Association for Cancer Research, US, US, (20111215), vol. 71, no. 24, Suppl.3, doi:10.1158/0008-5472.SABCS11-S5-6, ISSN 0008-5472, XP009168120
OPPOSITION- A Schneeweiss et al, "Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).", Cancer research, US, (20111215), vol. 71, no. 24, Suppl.3, doi:10.1158/0008-5472.SABCS11-S5-6, ISSN 0008-5472, XP009168120
OPPOSITION- F. Meric-Bernstam, Hung M.-C., "Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy", CLINICAL CANCER RESEARCH, American Association for Cancer Research, US, US, (20061101), vol. 12, no. 21, doi:10.1158/1078-0432.CCR-06-1732, ISSN 1078-0432, pages 6326 - 6330, XP055686438
OPPOSITION- Michael Untch, "Targeted Therapy for Early and Locally Advanced Breast Cancer", Breast Care, (20100616), vol. 5, doi:10.1159/000315047, pages 144 - 152, XP055686433
OPPOSITION- Gloria Fuentes;Maurizio Scaltriti;José Baselga;Chandra S Verma, "Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism", BREAST CANCER RESEARCH, Current Medicine Group Ltd., GB, GB, (20110522), vol. 13, no. 3, doi:10.1186/bcr2888, ISSN 1465-5411, page R54, XP021104479
OPPOSITION- M MARTY et al., "Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group", Journal of Clinical Oncology, (20050701), vol. 23, no. 19, pages 4265 - 4274, XP55685990
OPPOSITION- Nicholas Robert, Et Al, "Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer", Journal of Clinical Oncology, (20060620), vol. 24, no. 18, doi:10.1200/JCO.2005.04.1764, ISSN 0732-183X, pages 2786 - 2792, XP055686426
OPPOSITION- Nicholas Robert Et Al, "Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, US, (20060620), vol. 24, no. 18, doi:10.1200/JCO.2005.04.1764, ISSN 0732-183X, pages 2786 - 2792, XP055686426
OPPOSITION- ROBERT et al., "Randomized Phase III study of trastuzumab, Paclitaxel, and Carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer", J Clin Oncol, (20060620), vol. 24, pages 2786 - 2792, XP055686426
OPPOSITION- B.P. Coudert, Et Al, "Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)- 1 Trial", Journal of Clinical Oncology, (20070701), vol. 25, no. 19, pages 2678 - 2684, XP055685976
OPPOSITION- B P COUDERT et al., "Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)- 1 Trial", Journal of Clinical Oncology, (20070701), vol. 25, no. 19, pages 2678 - 2684, XP55685976
OPPOSITION- FORBES et al., "BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC", J. Clin.Oncol., (20060000), vol. 24, no. 18S, XP055693145
OPPOSITION- Forbes, Et Al, "BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC", J. Clin. Oncol., (20060620), vol. 24, no. 18S, XP055693145
OPPOSITION- BASELGA et al., "Phase II trial of Pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy", J Clin Oncol, (20100301), vol. 28, doi:10.1200/JCO.2009.24.2024, pages 1138 - 1144, XP055029441
OPPOSITION- BASELGA et al., "Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy", Journal of Clinical Oncology, (20100000), vol. 28, no. 7, doi:10.1200/JCO.2009.24.2024, pages 1138 - 1144, XP055029441
OPPOSITION- J. Baselga et al, "Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy", Journal of Clinical Oncology, (20100301), vol. 28, no. 7, doi:10.1200/JCO.2009.24.2024, ISSN 0732-183X, pages 1138 - 1144, XP055029441
OPPOSITION- J BASELGA et al., "Phase II Trial of Pertuzumab and Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy", Journal of Clinical Oncology, (20100301), vol. 28, no. 7, doi:10.1200/JCO.2009.24.2024, pages 1138 - 1144, XP055029441
OPPOSITION- V VALERO et al., "Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin and Trastuzumab As First-Line Chemotherapy for patients With HER2- Gene -Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens", Journal of Clinical Oncology, (20110110), vol. 29, no. 2, pages 149 - 156, XP55685992
OPPOSITION- R. Nahta, Gabriel N Hortobagyi, Francisco J, "Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention", The Oncologist, AlphaMed Press, (20030201), vol. 8, no. 1, doi:10.1634/theoncologist.8-1-5, ISSN 1083-7159, pages 5 - 17, XP055637555
OPPOSITION- Jieun Koh, Min Jung Kim, "Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage", Korean journal of radiology : official journal of the Korean Radiological Society, Korea (South), (20190101), vol. 20, no. 1, doi:10.3348/kjr.2018.0231, ISSN 1229-6929, page 69, XP055693550
OPPOSITION- J Lemieux, Et Al, "The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers", PRACTICE GUIDELINE SERIES, (20090101), vol. 16, no. 5, pages 48 - 57, XP055686260
OPPOSITION- Baselga Jos�; Swain Sandra M, "CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer", Clinical breast cancer, (20101201), vol. 10, no. 6, doi:10.3816/CBC.2010.n.065, ISSN 1938-0666, pages 489 - 491, XP009168129
OPPOSITION- J BASELGA et al., "CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer", Clinical Breast Cancer, (20101200), vol. 10, no. 6, doi:10.3816/CBC.2010.n.065, pages 489 - 491, XP009168129
OPPOSITION- L Fang, Z Barekati, B Zhang, Z Liu, Xy Zhong, "Targeted therapy in breast cancer: what's new?", SWISS MEDICAL WEEKLY, EMH SWISS MEDICAL PUBLISHERS, BASEL, CH, CH, doi:10.4414/smw.2011.13231, ISSN 1424-7860, XP055693538

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents